Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
IPRATROPIUM BROMIDE SALBUTAMOL SULFATE
Boehringer Ingelheim Limited
20/100mcg/ Mcg/Dose
Pressurised Inhalation Suspension
1994-04-14
IRISH MEDICINES BOARD ACTS 1995 AND 2006 MEDICINAL PRODUCTS(CONTROL OF PLACING ON THE MARKET)REGULATIONS,2007 (S.I. NO.540 OF 2007) PA0007/052/001 Case No: 2062024 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to BOEHRINGER INGELHEIM LIMITED ELLESFIELD AVENUE, BRACKNELL, BERKSHIRE RG12 8YS, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product COMBIVENT METERED AEROSOL 20 MICROGRAMS/100 MICROGRAMS PER METERED DOSE, PRESSURISED INHALATION SUSPENSION. The particulars of which are set out in Part I and Part II of the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 27/02/2009 until 12/11/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 14/04/2009_ _CRN 2062024_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT COMBIVENT Metered Aerosol 20 micrograms/100 micrograms per metered dose, Pressurised Inhalation Suspension. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each metered dose delivers 20 micrograms of ipratropium bromide (as monohydrate) and 100 micrograms of salbutamol (as sulphate). For excipients, see 6.1. 3 PHARMACEUTICAL FORM Pressurised inhalation, suspension. Pressurised aluminium container closed with a metering valve containing a creamy-white suspension inserted into a grey plastic actuator (mouthpiece). 4 CLINICAL PART Read the complete document